OncXerna Therapeutics

United States
Waltham, Massachusetts, United States, 02451

Company profile

OncXerna Therapeutics company profile

OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform. OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes. The company was founded in 2018 and was formerly known as Oncologie.

Business identity

Phone number
(781) 907 - 7810
Operating status
Closed
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2018-01-01, Year

Headquarters

Postal code
02451
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
3
Total equity funding
$126.5M
Last funding
Series Unknown / $30M / 2022-03-03
Last equity funding
Series Unknown / $30M
Investors
10
Lead investors
1
Founders
1
Articles
14
Closed on
2023-01-01

Founders and investors

Founders

Laura E. Benjamin

Lead investors

Nan Fung Life Sciences

Investors

K2 HealthVenturesKB InvestmentKorea Investment PartnersNan Fung Life SciencesPanacea Venture